RazorMetrics

AUSTIN, TX, December 20, 2024 – RazorMetrics, a leading innovator in pharmacy technology solutions, proudly announces that it has been named a winner of the prestigious Pinnacle Award for Business Performance & Excellence. The national prize recognizes RazorMetrics’ outstanding achievement in delivering solutions that make a substantive difference to people’s lives and setting a high bar in the pharmacy cost containment industry. https://lnkd.in/gw-X6Zpv

The popularity of GLP1-s is hitting a fever-pitch, with many touting that it’s a miracle weight loss drug, despite its eye-popping price tag. The high demand is creating a pressure point on health plans and employer pharmacy teams, making the expensive drug accessible to their members but not bankrupting the whole plan. According to a recent report from GoodRx, Americans spent more than $200 million on weight loss medications in 2024 alone. Continue reading: GLP-1s in 2025: High Demand, High Cost, Low Accessibility https://hubs.ly/Q0309GVq0

The amount of money the U.S. spends on healthcare is so mind numbingly large, that AHIP created the “healthcare dollar” image to help us all out. The healthcare dollar takes the whole medical spending budget and puts it into a picture of a dollar bill, separated into sections of costs (see picture below). The breakdown is helpful because it provides a visual of how medical expenses are allocated, simplifying a large and complex system. The picture helps companies like RazorMetrics see how much of the budget can be managed more effectively with the right solutions. Read More here: Healthcare Dollar Breakdown https://hubs.ly/Q02-J9yg0

According to a study presented at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium, the cisplatin shortage raised costs for practices within the U.S. Oncology Network by 16% for treating head and neck cancers. The increase was largely driven by the utilization of alternative drugs like cetuximab, whose average administration cost ($2,607) dwarfs that of cisplatin ($18). Read more: Drug Shortages Disrupting Care Continuity? https://hubs.ly/Q02-mJjK0

Come see us at the Florida Association of Health Plan (FAHP) Conference in Orlando this week. Booth 14!

A message on LinkedIn went viral recently. Angie Franks, CEO of Kalderos, posted about her husband’s experience going to the pharmacy to pick up his diabetes medication. In the past, this was a normal errand that cost an affordable $35 copay. But in March, he was slapped with a $965 bill. What happened? Why did the cost suddenly jump 2,600 percent? He didn’t know, and he decided not to buy his medication. Continue Reading: Heads Up: GLP-1s Are Shifting to the Medical Benefit https://hubs.ly/Q02ZgxGB0

Health Plan and Self-Funded Employer executives face an enormous challenge in managing rising drug costs, and the problem gets worse every year. Once promising Real Time Benefit Tools have floundered and driving formulary adherence remains difficult. There is hope. Join Siva Mohan, MD, an interventional cardiologist, and pharmacist Josh Canavan, PharmD, on December 5th for a behind-the-script look into the quickly evolving world of prescribing. Learn what really happens—the communication loop failure between physician, pharmacy, and health plans--with patients, prescribers, and pharmacists caught in the middle, how can we improve the system? Dr. Mohan and Dr. Canavan give insight into the processes causing friction and how new technologies are helping smooth the process to improve patient outcomes and lower costs. Learning Objectives: Learn how HealthTech is being used to significantly reduce pharmacy cost Learn about how physicians and pharmacists are dealing with communication inefficiencies and gain insights on how to improve the process to benefit your plan Hear real-world solutions to heart-breaking problems of pharmacy desert communities, polypharmacy patients, and unaffordable medication leading to damaging nonadherence Don’t miss this opportunity to hear firsthand insight from two medical professionals into a primary driver of high drug costs. You’ll learn how you can take control of costs by coordinating and automating communication between stakeholders to drive formulary adherence to lower costs.

Overdose deaths decreased 14% partly due to availability of naloxone, the generic and affordable version of the overdose-reversing drug Narcan. #accessibledrugs https://hubs.ly/Q02YfvF30

Humira has fallen off its throne. For years, it was the world’s top-selling drug, generating more than $20 billion in annual sales at its peak in 2021 for AbbVie. But then, Humira’s patent ran out, paving the way for a flood of competitive alternatives. AbbVie knew this was coming, and in a surprising shift, Skyrizi – another AbbVie brand – overtook its Humira market instead of the cheaper biosimilar versions of Humira (aka adalimumab). Retaining high sales demonstrates how the company successfully employed “product hopping” tactics, which has raised concerns about the viability of biosimilar competition. Read more about Product Hopping here: https://hubs.ly/Q02Ygfcz0

Do you hate waiting in line? If yes, you are not alone. That's why mail-order pharmacy is taking off. Let RazorMetrics help you avoid the torture. #accessible drugs https://hubs.ly/Q02Y96cG0